1. Traxinger K, Kelly C, Johnson BA, Lyles RH, Glass JD. Prognosis and epide‑ miology of amyotrophic lateral sclerosis: Analysis of a clinic population, 1997–2011. Neurol Clin Pract. 2013;3(4):313–20.
2. Gasco S, Zaragoza P, Garcia‑Redondo A, Calvo AC, Osta R. Inflammatory and non‑inflammatory monocytes as novel prognostic biomarkers of survival in SOD1G93A mouse model of Amyotrophic Lateral Sclerosis. PLoS ONE. 2017;12(9):e0184626.
3. Musaro A. State of the art and the dark side of amyotrophic lateral sclero‑ sis. World J Biol Chem. 2010;1(5):62–8.
4. Pramatarova A, Laganiere J, Roussel J, Brisebois K, Rouleau GA. Neuron‑ specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci. 2001;21(10):3369–74.
5. Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, Rule M, McMahon AP, Doucette W, Siwek D, Ferrante RJ, et al. Wild‑type nonneu‑ ronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003;302(5642):113–7.
6. Gallagher G, Dickensheets H, Eskdale J, Izotova LS, Mirochnitchenko OV, Peat JD, Vazquez N, Pestka S, Donnelly RP, Kotenko SV. Cloning, expression and initial characterization of interleukin‑19 (IL‑19), a novel homologue of human interleukin‑10 (IL‑10). Genes Immun. 2000;1(7):442–50.
7. Sabat R, Wallace E, Endesfelder S, Wolk K. IL‑19 and IL‑20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets. 2007;11(5):601–12.
8. Parrish‑Novak J, Xu W, Brender T, Yao L, Jones C, West J, Brandt C, Jelinek L, Madden K, McKernan PA, et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor‑ ligand interactions mediate unique biological functions. J Biol Chem. 2002;277(49):47517–23.
9. Horiuchi H, Parajuli B, Wang Y, Azuma YT, Mizuno T, Takeuchi H, Suzumura A. Interleukin‑19 acts as a negative autocrine regulator of activated microglia. PLoS ONE. 2015;10(3):e0118640.
10. Azuma YT, Matsuo Y, Kuwamura M, Yancopoulos GD, Valenzuela DM, Murphy AJ, Nakajima H, Karow M, Takeuchi T. Interleukin‑19 protects mice from innate‑mediated colonic inflammation. Inflamm Bowel Dis. 2010;16(6):1017–28.
11. Cooley ID, Chauhan VS, Donneyz MA, Marriott I. Astrocytes produce IL‑19 in response to bacterial challenge and are sensitive to the immunosup‑ pressive effects of this IL‑10 family member. Glia. 2014;62(5):818–28.
12. Matsuo Y, Azuma YT, Kuwamura M, Kuramoto N, Nishiyama K, Yoshida N, Ikeda Y, Fujimoto Y, Nakajima H, Takeuchi T. Interleukin 19 reduces inflam‑ mation in chemically induced experimental colitis. Int Immunopharma‑ col. 2015;29(2):468–75.
13. Fujimoto Y, Fujita T, Kuramoto N, Kuwamura M, Izawa T, Nishiyama K, Yoshida N, Nakajima H, Takeuchi T, Azuma YT. The role of interleukin‑19 in contact hypersensitivity. Biol Pharm Bull. 2018;41(2):182–9.
14. Xie W, Fang L, Gan S, Xuan H. Interleukin‑19 alleviates brain injury by anti‑ inflammatory effects in a mice model of focal cerebral ischemia. Brain Res. 2016;1650:172–7.
15. Guo J, Wang H, Li L, Yuan Y, Shi X, Hou S. Treatment with IL‑19 improves locomotor functional recovery after contusion trauma to the spinal cord. Br J Pharmacol. 2018;175(13):2611–21.
16. Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL‑19 induces production of IL‑6 and TNF‑alpha and results in cell apoptosis through TNF‑alpha. J Immunol. 2002;169(8):4288–97.
17. Hsu YH, Hsieh PP, Chang MS. Interleukin‑19 blockade attenuates colla‑ gen‑induced arthritis in rats. Rheumatology (Oxford). 2012;51(3):434–42.
18. Zhong H, Wu Y, Belardinelli L, Zeng D. A2B adenosine receptors induce IL‑19 from bronchial epithelial cells, resulting in TNF‑alpha increase. Am J Respir Cell Mol Biol. 2006;35(5):587–92.
19. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, et al. Motor neuron degenera‑ tion in mice that express a human Cu Zn superoxide dismutase mutation. Science. 1994;264(5166):1772–5.
20. Takeuchi H, Mizoguchi H, Doi Y, Jin S, Noda M, Liang J, Li H, Zhou Y, Mori R, Yasuoka S, et al. Blockade of gap junction hemichannel suppresse disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer’s disease. PLoS ONE. 2011;6(6):e21108.
21. Hayworth CR, Gonzalez‑Lima F. Pre‑symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1(G93A) ALS mouse model. Neuroscience. 2009;164(3):975–85.
22. Suzumura A, Mezitis SG, Gonatas NK, Silberberg DH. MHC antigen expres‑ sion on bulk isolated macrophage‑microglia from newborn mouse brain: induction of Ia antigen expression by gamma‑interferon. J Neuroimmu‑ nol. 1987;15(3):263–78.
23. Liang J, Takeuchi H, Doi Y, Kawanokuchi J, Sonobe Y, Jin S, Yawata I, Li H, Yasuoka S, Mizuno T, et al. Excitatory amino acid transporter expression by astrocytes is neuroprotective against microglial excitotoxicity. Brain Res. 2008;1210:11–9.
24. Komiya H, Takeuchi H, Ogawa Y, Hatooka Y, Takahashi K, Katsumoto A, Kubota S, Nakamura H, Kunii M, Tada M, et al. CCR2 is localized in micro‑ glia and neurons, as well as infiltrating monocytes, in the lumbar spinal cord of ALS mice. Mol Brain. 2020;13(1):64.
25. Kuno R, Yoshida Y, Nitta A, Nabeshima T, Wang J, Sonobe Y, Kawanokuchi J, Takeuchi H, Mizuno T, Suzumura A. The role of TNF‑alpha and its receptors in the production of NGF and GDNF by astrocytes. Brain Res. 2006;1116(1):12–8.
26. Zhao W, Beers DR, Henkel JS, Zhang W, Urushitani M, Julien JP, Appel SH. Extracellular mutant SOD1 induces microglial‑mediated motoneuron injury. Glia. 2010;58(2):231–43.
27. Lee JY, Lee JD, Phipps S, Noakes PG, Woodruff TM. Absence of toll‑like receptor 4 (TLR4) extends survival in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2015;12:90.
28. Horiuchi H, Parajuli B, Komiya H, Ogawa Y, Jin S, Takahashi K, Azuma YT, Tanaka F, Suzumura A, Takeuchi H. Interleukin‑19 abrogates experimental autoimmune encephalomyelitis by attenuating antigen‑presenting cell activation. Front Immunol. 2021;12:615898.
29. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, Przed‑ borski S. Astrocytes expressing ALS‑linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10(5):615–22.
30. Hensley K, Abdel‑Moaty H, Hunter J, Mhatre M, Mou S, Nguyen K, Potapova T, Pye QN, Qi M, Rice H, et al. Primary glia expressing the G93A‑ SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J Neuroinflammation. 2006;3:2.
31. Kawaguchi‑Niida M, Yamamoto T, Kato Y, Inose Y, Shibata N. MCP‑1/CCR2 signaling‑mediated astrocytosis is accelerated in a transgenic mouse model of SOD1‑mutated familial ALS. Acta Neuropathol Commun. 2013;1:21.
32. Kuno R, Wang J, Kawanokuchi J, Takeuchi H, Mizuno T, Suzumura A. Auto‑ crine activation of microglia by tumor necrosis factor‑alpha. J Neuroim‑ munol. 2005;162(1–2):89–96.
33. Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y, Mizuno T, Suzumura A. Tumor necrosis factor‑alpha induces neurotoxic‑ ity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem. 2006;281(30):21362–8.
34. Horiuchi H, Parajuli B, Kawanokuchi J, Jin S, Mizuno T, Takeuchi H, Suzumura A. Oligomeric amyloid β facilitates microglial excitotoxicity by upregulating tumor necrosis factor‑α and downregulating excita‑ tory amino acid transporter 2 in astrocytes. Clin Exp Neuroimmunol. 2015;6(2):183–90.
35. Brambilla L, Guidotti G, Martorana F, Iyer AM, Aronica E, Valori CF, Rossi D. Disruption of the astrocytic TNFR1‑GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis. Hum Mol Genet. 2016;25(14):3080–95.
36. Tortarolo M, Vallarola A, Lidonnici D, Battaglia E, Gensano F, Spaltro G, Fiordaliso F, Corbelli A, Garetto S, Martini E, et al. Lack of TNF‑alpha receptor type 2 protects motor neurons in a cellular model of amyo‑trophic lateral sclerosis and in mutant SOD1 mice but does not affect disease progression. J Neurochem. 2015;135(1):109–24.
37. Chen SH, Oyarzabal EA, Sung YF, Chu CH, Wang Q, Chen SL, Lu RB, Hong JS. Microglial regulation of immunological and neuroprotective functions of astroglia. Glia. 2015;63(1):118–31.
38. Henkel JS, Beers DR, Zhao W, Appel SH. Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol. 2009;4(4):389–98.
39. Stoll G, Jander S, Schroeter M. Cytokines in CNS disorders: neurotoxicity versus neuroprotection. J Neural Transm Suppl. 2000;59:81–9.
40. Endo F, Komine O, Fujimori‑Tonou N, Katsuno M, Jin S, Watanabe S, Sobue G, Dezawa M, Wyss‑Coray T, Yamanaka K. Astrocyte‑derived TGF‑β1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep. 2015;11(4):592–604.
41. Chakrabarty P, Li A, Ceballos‑Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario AM, Cruz PE, Verbeeck C, et al. IL‑10 alters immu‑ noproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron. 2015;85(3):519–33.
42. Guillot‑Sestier MV, Doty KR, Gate D, Rodriguez J Jr, Leung BP, Rezai‑ Zadeh K, Town T. Il10 deficiency rebalances innate immunity to mitigate Alzheimer‑like pathology. Neuron. 2015;85(3):534–48.
43. Moynagh PN. The interleukin‑1 signalling pathway in astrocytes: a key contributor to inflammation in the brain. J Anat. 2005;207(3):265–9.
44. Sakurai N, Kuroiwa T, Ikeuchi H, Hiramatsu N, Maeshima A, Kaneko Y, Hiromura K, Nojima Y. Expression of IL‑19 and its receptors in RA: potential role for synovial hyperplasia formation. Rheumatology (Oxford). 2008;47(6):815–20.
45. Steinert A, Linas I, Kaya B, Ibrahim M, Schlitzer A, Hruz P, Radulovic K, Terracciano L, Macpherson AJ, Niess JH. The stimulation of mac‑ rophages with TLR ligands supports increased IL‑19 expression in inflammatory bowel disease patients and in colitis models. J Immunol. 2017;199(7):2570–84.
論文の公開元へ
